Pregnancy outcome after cabergoline treatment in early weeks of gestation.
We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies resulted in 12 (19.7%) early terminations (five induced abortions, six spontaneous abortions, one hydatidiform mole) and 49 (80.3%) live births. In one case, malformations were suspected by a gynecologist based on ultrasound at 12 gestational weeks and the pregnancy was terminated; additional information was not available. There was one case of trisomy 18. The frequency of spontaneous and induced abortions and major congenital malformations was comparable with rates in the general population. The data did not indicate any potential adverse effect of the drug on pregnancy. The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.
Ricci
Elena
E
Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea 62-20157, Milan, Italy. ricci@marionegri.it
Parazzini
Fabio
F
Motta
Tiziano
T
Ferrari
Carlo I
CI
Colao
Annamaria
A
Clavenna
Antonio
A
Rocchi
Francesca
F
Gangi
Emanuela
E
Paracchi
Sandra
S
Gasperi
Maurizio
M
Lavezzari
Maurizio
M
Nicolosi
Anna Elisa
AE
Ferrero
Simona
S
Landi
Maria Luisa
ML
Beck-Peccoz
Paolo
P
Bonati
Maurizio
M
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D000022:Abortion, Spontaneous / Q000453:epidemiology; D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005865:Gestational Age; D006801:Humans; D007558:Italy / Q000453:epidemiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline